|Mr. Kevin T. Conroy||Chairman, Pres & CEO||1.92M||N/A||1966|
|Mr. Jeffrey T. Elliott CFA||Exec. VP, CFO & COO||847.38k||485.04k||1978|
|Mr. D. Scott Coward||Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec.||826.6k||2.57M||1965|
|Mr. Graham P. Lidgard||Emeritus Chief Science Officer||852.84k||1.01M||1949|
|Mr. Jake Orville||Gen. Mang. of Pipeline||651.43k||N/A||1974|
|Mr. Gary Frings||Chief Information Officer||N/A||N/A||N/A|
|Dr. Scott C. Johnson Ph.D.||Chief Science Officer and Sr. VP of R&D||N/A||N/A||N/A|
|Ms. Megan Jones||Associate Mang. of Investor Relations||N/A||N/A||N/A|
|Mr. Tim Caprez||Chief Compliance Counsel & VP||N/A||N/A||N/A|
|Mr. Vic Parker||Head of Sales||N/A||N/A||N/A|
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Exact Sciences Corporation’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 6; Compensation: 10.